Cover news reporter Meng Meiyi Yili

BGI disclosed its annual report on April 23, 2022. The company achieved a total operating revenue of 6.77 billion yuan in 2021, a year-on-year decrease of 19.4%; The net profit attributable to the parent company was 1.46 billion, a year-on-year decrease of 30.1%; Earnings per share was 3.56 yuan. In the first quarter of 2022, the company achieved a total operating revenue of 1.43 billion, a year-on-year decrease of 8.5%; The net profit attributable to the parent company was 330 million, a year-on-year decrease of 37.1%. Covid-19, SUNCOO life science CEO Jennifer Zhan analysis shows that the recent decline in the Chinese gene is mainly affected by the new crown pneumonia epidemic situation and the changes in the overseas situation. In the future, we should focus on the R & D and application of new products.

Jennifer Zhan said that novel coronavirus pneumonia will not disappear in the near future, so the revenue of the Chinese big gene business will continue, but the competition is fierce. With the contraction of overseas epidemic detection business and the growth of domestic epidemic detection demand, the business income of BGI may show a flat or slight growth trend in the future.

For the new growth point in the future, Jennifer Zhan believes that it is a new product of BGI - gene testing. There is a time course from R & D investment to product output. With the gradual deepening of market recognition of gene testing in recent years, it is expected to open up a large market in the future. There are also fireeye laboratories around the world, which are actually an upgraded version of the epidemic response, but we can’t give this too high hope.

Jennifer Zhan concluded, “In fact, BGI has a solid foundation and advanced technology. It should focus on the R & D and application of new products. The new crown testing business can not be used as a long-term profit growth point. If the construction and channels of overseas platforms are only applicable to the new crown testing, they are relatively weak. If these channels can be used to expand the testing services of new products, the company will have great prospects in the future.”